Numis Corporation PLC
22 December 2000
Numis Corporation Plc ('Numis' or 'the Company')
Grant of and cancellation of options
Background
At an Extraordinary General Meeting of shareholders held on 25 April 2000,
shareholders approved a change in the limit of the Company's two executive
share option schemes so as to permit the grant of options over 20% of the
issued ordinary share capital from time to time. The limit less the number of
outstanding options over ordinary shares (headroom) is 407,400. In order that
Numis can grant new options and maintain a headroom figure, certain directors
of the Company have agreed to the cancellation of various options:
Cancellation of options
Director's Position in No of options % of shares Total no of % of shares
name Numis cancelled in issue options now held in issue
Oliver Chief 112,500 0.75 362,500 2.41
Hemsley Executive
Charles Executive 15,000 0.10 185,000 1.23
Crick Director
David Non-Executive 56,250 0.37 56,250 0.37
Craig Chairman
Paul Non-Executive 10,000 0.07 40,000 0.27
Gaunt Director
Michael Non-Executive 56,250 0.37 81,250 0.54
Sinclair Director
Totals 250,000 1.66 725,000 4.82
The options over ordinary shares granted to Oliver Hemsley, David Craig, Paul
Gaunt and Michael Sinclair were granted on 28 March 2000. They were subject
to performance criteria, as follows:
a) One half of the options granted over ordinary shares were
exercisable at 292.5p provided that the mid-market price of Numis shares was
in excess of 500p for any consecutive 60 day period from the date of grant of
the options to 3 years after that date (and on the date of exercise) and that
the Numis share price during that 3 year period and up to the day the options
were exercised, had out-performed the FT All Share Index. The options were
not allowed to be exercised earlier than 3 years or later than 10 years after
the date of grant.
b) One half of the options granted over ordinary shares were
exercisable at 292.5p provided that the mid-market price of Numis shares was
in excess of 700p for any consecutive 60 day period from the date of grant of
the options to 3 years after that date (and on the date of exercise) and that
the Numis share price during that 3 year period and up to the day the options
were exercised, had out-performed the FT All Share Index. The options were
not allowed to be exercised earlier than 3 years or later than 10 years after
the date of grant.
The 15,000 options over ordinary shares granted to Charles Crick were granted
on 28 March 2000 at an exercise price of 292.5p and were exercisable no
earlier than 3 years or later than 10 years after the date of grant.
Grant of options
The Board of Numis announces that it has, on 21 December 2000, granted options
over 518,000 Numis ordinary shares to individuals due to join the Company's
new North West office and an existing employee. This represents 3.4% of the
issued ordinary share capital. These options are exercisable at a
subscription price of 207p after 21 December 2003 but before 21 December 2010.
The ordinary shares referred to in this announcement are the ordinary shares
of 25p each in Numis Corporation Plc.
21 December 2000
END
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.